Lertal®, a multicomponent nutraceutical, could reduce the use of antihistamines in children with allergic rhinoconjunctivitis

Main Article Content

Maria Angela Tosca
Roberta Olcese
Guido Marinelli
Maria Papale
Anna Maria Zicari
Gianluigi Marseglia
Giorgio Ciprandi

Keywords

nutraceutical, medication use, children, antihistamines, allergic rhinitis

Abstract

Antihistamines are the cornerstone treatment of allergic rhinitis (AR). To quantify the antihistaminic consume is particularly relevant in clinical practice, since a remarkable use is usually associated with severe symptoms. The aim of the study was to measure the use of antihistamines in two groups of children suffering from AR. The first group took a course of a nutraceutical (Lertal®) before the observation (active group, AG); a second one was considered as control (control group, CG). Both groups took antihistamines on demand. The children were visited at baseline and after 1 year. The number of days of antihistaminic use was the primary outcome. Children in AG had a significant reduced number of antihistamines use in comparison with CG (p=0.008). In conclusion, the current study showed that a course with a multicomponent nutraceutical could reduce the use of symptomatic antihistamines in children with allergic rhinoconjuncti- vitis.

a

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Abstract 59 | PDF Downloads 34

References

1) Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8:108-352
2) Méndez-Enríquez E, Hallgren J. Mast Cells and Their Progenitors in Allergic Asthma. Front Immunol. 2019;10:821
3) Wallace DV, Dykewicz MS, Oppenheimer J, Portnoy JM, Lang DM. Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance From the 2017 Joint Task Force on Practice Parameters. Ann Intern Med. 2017;167:876-881
4) Ciprandi G, La Mantia I. VAS for assessing the perception of antihistamines use in allergic rhinitis. Acta Biomed. 2019;90(7-S):41-44
5) Didier A, Wahn U, Horak F, Cox LS. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol. 2014;10:1309-24
6) Hafner D, Reich K, Matricardi PM, Meyer H, Kettner J, Narkus A. Perspective validation of Allergy-Control-Score: a novel symptom-medicatiuon sxore for clinical trials. Allergy 2011;66:629-36
7) Ciprandi G, Tosca MA, Marseglia GL, Klersy C. Relationships between allergic inflammation and nasal airflow in children with seasonal allergic rhinitis. Annals Allergy Asthma Immunol 2005;94:258-61
8) Ciprandi G, Cirillo I, Vizzaccaro A, Milanese M, Tosca MA. Nasal obstruction in patients with seasonal allergic rhinitis: relationships between allergic inflammation and nasal airflow. Int Arch Allergy Immunol 2004;134:34-40
9) Marseglia GL, Licari A, Ciprandi G. A polycentric, randomized, double blind, parallel-group, placebo-controlled study on Lertal®, a multicomponent nutraceutical, as add-on treatment in children with allergic rhinoconjunctivitis: Phase I during active treatment. J Biol Reg 2019;33:617-622
10) Marseglia GL, Licari A, Leonardi S, Papale M, Zicari AM, Schiavi L, et al. A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nutraceutical, as preventive treatment in children with allergic rhinoconjunctivitis: Phase II. Ital J Ped 2019;45:84
11) Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958
12) Ciprandi G, Cosentino C, Milanese M, Mondino C, Canonica GW. Fexofenadine reduces nasal congestion in perennial allergic rhinitis Allergy 2001;56:1068-1070
13) Ciprandi G, Pronzato C, Ricca V, Varese P, Giacco GS, Canonica G. Terfenadine exerts antiallergic activity reducing ICAM‐1 expression on nasal epithelial cells in patients with pollen allergy. Clinical Experimental Allergy 1995;25:871-878
14) Ciprandi G, Buscaglia S, Catrullo A, Pesce GP, Fiorino N, Montagna P, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti‐allergic activity. Clinical Experimental Allergy 1997;27:182-91
15) Ciprandi G, Tosca MA, Passalacqua G, Canonica GW. Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Annals of Allergy Asthma Immunol 2001;87:222-6
16) Yepes-Nunes JJ, Brozek JL, Fiocchi A, Pawankar R, Cuello-Garcia C, Zhang Y, et al. Vitamin D supplementation in primary allergy prevention: systematic review of randomized and non-randomized studies. Allergy 2018;73:37-49
17) Kim YH, Kim KW, Kim MJ, Sol IS, Yoon SH, Ahn HS, et al. Vitamin D levels in allergic rhinitis: a systematic review and meta-analysis. Ped Allergy Immunol 2016;27:580-90
18) Aryan Z, Rezaei N, Camargo CA. Vitamin status, aeroallergen sensitization, and allergic rhinitis: a systematic review and meta-analysis. Int Rev Immunol 2017;36:41-53
19) Yu H, Qiu JF, Ma LJ, Hu YJ, Li P, Wan JB. Phytochemical and phytopharmacological review of Perilla frutescens L. (Labiatae), a traditional edible-medicinal herb in China. Food Chem Toxicol. 2017;108(Pt B):375-391
20) Igarashi M, Miyazaki Y. A review on bioactivities of Perilla: progress in research on the functions of Perilla as medicine and food. Evid Based Complement Alternat Med 2013;2013:925342.
21) Chirumbolo S. The role of Quercetin, Flavonols and Flavones in modulating inflammatory cell function. Inflamm Allergy-Drug Targets 2010; 9(4):263-85.
Mlcek J, Jurikova T, Skrovankova S, Sochor J. Quercetin and its anti-allergic immune response. Molecules 2016;21,623

Most read articles by the same author(s)